報價延遲最少15分鐘:2025/05/31 11:57 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
2.095 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-12.30/-5.40
|
|
企業價值
16.78M
|
| 資產負債 |
|
每股賬面淨值
2.55
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
400.00K
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/05/31 11:57 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| CEL-SCI Corp is a player in the biotechnology sector. It is engaged in the research and development of the treatment of cancer and other diseases using the immune system. The Company's core capabilities include drug discovery, research, development, and manufacturing of complex biological substances. It is focused on the development of Multikine (Leukocyte Interleukin, Injection), investigational immunotherapy under development for the treatment of certain head and neck cancers, and anal warts or cervical dysplasia. |